


## 5-LO/mPGES1-IN-1

Cat. No.:	HY-126898
CAS No.:	1492060-44-2
Molecular Formula:	C <sub>25</sub> H <sub>25</sub> ClN <sub>4</sub> O <sub>2</sub> S <sub>2</sub>
Molecular Weight:	513.07
Target:	Lipoxygenase; PGE synthase
Pathway:	Metabolic Enzyme/Protease; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	5-LO/mPGES1-IN-1 (Compound 16) is a dual inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LO). IC <sub>50</sub> values are 0.3 and 0.4 μM, respectively. 5-LO/mPGES1-IN-1 has anti-inflammatory activity <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	5-LOX 0.4 μM (IC <sub>50</sub> )								
<b>In Vivo</b>	<p>5-LO/mPGES1-IN-1 (10 mg/kg, intraperitoneally injected, pretreated 30 minutes before peritonitis induction) reduces vascular permeability and inflammatory cell infiltration in zymosan-induced mouse peritonitis models. Impaired cysteine-leukotriene and prostaglandin E2 levels<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Zymosan-Induced Peritonitis in Mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p. pretreated 30 minutes before peritonitis induction</td> </tr> <tr> <td>Result:</td> <td>Reduced vascular permeability by 57% and inhibited neutrophil infiltration by 45%.</td> </tr> </table>	Animal Model:	Zymosan-Induced Peritonitis in Mice <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	i.p. pretreated 30 minutes before peritonitis induction	Result:	Reduced vascular permeability by 57% and inhibited neutrophil infiltration by 45%.
Animal Model:	Zymosan-Induced Peritonitis in Mice <sup>[1]</sup>								
Dosage:	10 mg/kg								
Administration:	i.p. pretreated 30 minutes before peritonitis induction								
Result:	Reduced vascular permeability by 57% and inhibited neutrophil infiltration by 45%.								

### REFERENCES

[1]. Hanke T, et al. Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo. J Med Chem. 2013 Nov 27;56(22):9031-44.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA